Acanthosis nigricans was observed 3 months after single lung transplantation in a 51-year-old African American woman with idiopathic pulmonary fibrosis. The patient had no endocrinological abnormalities and was not taking any medications known to cause acanthosis nigricans; extensive investigation did not reveal an underlying malignant process. Because acanthosis nigricans may occur as a paraneoplastic phenomenon, it is important to rule out an underlying malignancy. This is especially important in solid-organ transplant recipients receiving chronic immunosuppressive therapy.
Get full access to this article
View all access options for this article.
References
1.
RafiAGhachaRSinhaAIssamAMohammadI. Spectrum of skin disease in renal transplant recipients. Dial Transplant.2001;30:282–285.
2.
GoldsteinGDGollubSCrillB. Cutaneous complication of heart transplantation. J Heart Transplant.1986;5:143–147.
3.
IfrahNBergerFSaint-AndreJMartiatPGardembas-PainMBoassonM. Transient acanthosis nigricans following bone marrow transplantation for lymphoid malignancy. Bone Marrow Transplant.1990;5:281–282.
4.
FargnoliMCFrascioneP. Images in clinical medicine. Acanthosis nigricans. N Engl J Med.2005;353:2797.
5.
MatsookaLYWortsmanJGavinJRGoldmanJ. Spectrum of endocrine abnormalities associated with acanthosis nigricans. Am J Med.1987;83:719–725.
6.
HudJAJrCohenJBWagnerJMCruzPDJr. Prevalence and significance of acanthosis nigricans in adult obese population. Arch Dermatol.1992;128:941–944.
7.
BarbieriRLRyanKJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: A common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol.1983;147:90–101.
8.
BairdJSJohnsonJLElliot-MillsDOpasLM. Systemic lupus erythematous with acanthosis nigricans hyperpigmentation and insulin receptor antibody. Lupus.1997;6:275–278.
McKennnyJMProctorJDHarrisSChinchiliVM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patientsJAMA.1994;271:672–677.
11.
SafaiBGrantJMKurtzRLightdaleCJCoodRA. Cutaneous manifestation of internal malignancies: Acanthosis nigricans. Int J Dermatol.1978;17:312–315.
12.
ChakrabartyANormanRPhillipsT. Cutaneous manifestations of diabetes. Wounds.2002;14:267–274.
13.
OlsonKK. Acanthosis nigricans. A guide to assessment and evaluation. Adv Nurse Pract.2004;12:24–26.
14.
CharnvisesKWeerakietSTingthanatikulYWansumrithSChanprasertyothinSRojanasakulA. Acanthosis nigricans: Clinical predictor of abnormal glucose tolerance in Asian women with polycystic ovary syndrome. Gynecol Endocrinol.2005;21:161–164.
15.
BairdJSJohnsonJLElliott-MillsDOpasLM. Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody. Lupus.1997;6:275–278.
16.
MurASeidelVLopez-VichezMABonetMGilaberteM. Acanthosis nigricans as an adverse effect of highly active antiretroviral therapy in an adolescent girl with human immunodeficiency virus infection. Pediatr Infect Dis J.2005;24:742–743.
17.
GleichmannEPalsSRolinkARadasiewiczTGleichmannH. Graft versus host reactions—clues to the etiopathology of a spectrum of immunological disease. Immunol Today.1984;5:324–326.
18.
PennI. Cancers complicating organ transplantation. N Engl J Med.1990;323:1767–1769.
19.
YehJSMunnSEPlunkettTAHarperPGHopsterDJdu VivierAW. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: A case report and literature review. J Am Acad Dermatol.2000;42:357–362.
20.
LeeHWSuhHSChoiJC. Hyperkeratosis of the nipple and areola as a sign of malignant acanthosis nigricans. Clin Exp Dematol.2005;30:721–722.
